Abstract
Background TSH-secreting tumours are extremely rare case of hyperthyroidism. Most important clinical feature is preserved TSH level in subjects with apparent thyrotoxicosis. Possible misdiagnosis of primary thyroid hyperfunction could lead to mistreatment with anti-thyroid medications. This worsens disease course and outcome. Neurosurgery success rate is limited by tumour size and its extrasellar expansion. Native somatostatin is key negative regulator of TSH secretion. In most cases tumour cells express somatostatin receptors. This feature creates potential use of somatostatin analogues for medical treatment of TSHsecreting tumours.
Highlights
TSH-secreting tumours are extremely rare case of hyperthyroidism
Neurosurgery success rate is limited by tumour size and its extrasellar expansion
Initially, all patients had elevated fT4 and a-SU levels. 3 months of octreotide long acting repeatable (LAR) therapy led to significant fT4 reduction and TSH reduction from mean 6.5 mIU/ml to 0.3 mIU/l)
Summary
The role of somatostatin analogues in treatment of TSH secreting pituitary adenomas Wojciech Zgliczyński1*, Piotr Zdunowski, Izabella Czajka-Oraniec, Wojciech Jeske, Grzegorz Zieliński. From 4th Congress of the Polish Thyroid Association 2013 Lodz, Poland. From 4th Congress of the Polish Thyroid Association 2013 Lodz, Poland. 11-13 April 2013
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
